Donanemab – what we know about the latest Alzheimer’s drug
Donanemab can slow the progression of Alzheimer’s disease.But what is the drug and how does it work? Here your questions on ...
STAT15h
U.K.’s cost-effectiveness agency says Alzheimer’s drug donanemab does not provide good value
For the second time in recent months, a U.K. agency said the limited benefits of a new Alzheimer’s drug do not justify its ...
Outsourcing-pharma9h
NICE rejects Donanemab for NHS use despite MHRA approval
Donanemab marks a significant advancement in Alzheimer’s treatment, but NHS patients face a setback with NICE's rejection of ...
Alzheimer’s wonder drug blocked on NHS over cost
The most effective drug for Alzheimer’s has been blocked for use on the NHS. Regulators have declared the new treatment for ...
New Alzheimer’s drugs should be available on NHS, says patient’s wife
A wife whose husband will not be eligible for new Alzheimer’s drugs has implored health leaders to ensure that others like ...
National Institute for Health and Care Excellence15h
New Alzheimer’s treatment donanemab does not currently demonstrate value for the NHS says NICE
Donanemab (also called Kisunla and made by Eli Lilly) has been licensed today by the MHRA for treatment of mild cognitive impairment or mild dementia due to Alzheimer’s disease in some adults. It is a ...
Donanemab: Everything we know about the latest Alzheimer’s drug rejected by the NHS
Donanemab: Everything we know about the latest Alzheimer’s drug rejected by the NHS - Donanemab and another new drug for ...
ITV5h
Alzheimer’s drug rejected for NHS use: What is Donanemab?
Donanemab is a targeted antibody drug which slows the early stages of Alzheimer’s. Alzheimer’s Research UK said Nice's announcement “risks signalling that the UK is no longer a good place to ...